A new advanced artificial intelligence (AI) algorithm more accurately model how genes associated with specific autoimmune diseases are expressed and regulated and to identify additional genes of risk.

Autoimmune diseases often present with overlapping, non-specific symptoms that complicate timely diagnosis and treatment. This complexity is magnified for individuals with polyautoimmunity, ...

Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief ...

Exagen Inc. has appointed Dr. Michael Mahler as Chief Scientific Officer, recognizing his extensive expertise in immunology and autoimmune research. Dr. Mahler earned his Ph.D. from the University of ...

Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...